TrialESC heart failure2021

Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.

Julie Kolwelter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.